Sector News

AstraZeneca CEO's reported exit remains a mystery

July 17, 2017
Life sciences

The mystery surrounding the intentions of the chief executive of AstraZeneca PLC, one of the world’s largest pharmaceutical firms, remains…a mystery.

Two days after an Israeli news report said Chief Executive Pascal Soriot had agreed to take the top job at a rival drug giant, Israel-based Teva Pharmaceutical Industries Ltd., AstraZeneca continues to say it won’t comment, labeling that report — and more recent reports that he is staying on — as market rumors and speculation.

A spokesman late Friday said Dr. Soriot would host the presentation of the company’s midyear financial results, expected later this month. But the spokesman declined to say whether that indicated Dr. Soriot was sticking around for the longer term.

A spokesman for Teva said it also wouldn’t comment on market rumors.

Shares of AstraZeneca fell sharply Thursday, after an Israeli news site, Calcalist, reported the day before that Dr. Soriot had agreed to take the top job at Teva. They ended London trading down more than 3%. Despite the steep stock market drop, AstraZeneca has repeatedly stopped short of denying the report.

On Friday, shares finished lower for the second day running, falling another 0.29%, amid the uncertainty.

By Chip Cummins

Source: Market Watch

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach